Q2: Plus Therapeutics Beats Estimates, Eos Energy Falls Short
- August 14th, 2023
- 447 views
Plus Therapeutics, Inc. (Nasdaq: PSTV), a pharmaceutical company, delivered a second-quarter 2023 loss of $(0.59) per share, surpassing the consensus estimate loss of $(1.91) per share. The company posted quarterly sales of $1.85 million, outperforming analysts' anticipated revenue of $790 thousand.
$PSTV was trading at $2.70 in after-hours, up $0.20 (+8.00%)
Meanwhile, Eos Energy Enterprises, Inc. (Nasdaq: EOSE), a player in the energy sector, reported a Q2 2023 loss of $(1.12) per share, falling short of the consensus estimate loss of $(0.37) per share. Additionally, the company generated quarterly sales of $249.00 thousand, missing analysts' projected revenue of $2.33 million for the period.
In after-hours, $EOSE was trading at $2.37, down $0.01 (-0.42%)
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
FTC Takes Action to Prevent Anticompetitive Arrangement in Beretta, Ruger Deal
September 16th, 2026Why Opponent Preparation Matters for Post-Graduate Athletes
September 16th, 2026The Work Behind the Game: How Football Teams Prepare to Compete
September 15th, 2026NJCP Operates on a Prep Model Built Around a Full Season
September 14th, 2026Earnings Preview: High Tide, Kestra Medical, and RF Industries in Focus
September 12th, 2026
Member Login